CRISPR Therapeutics AG - Common Shares (CRSP)
43.63
+2.05 (4.93%)
NASDAQ · Last Trade: Jun 17th, 11:48 AM EDT
Detailed Quote
Previous Close | 41.58 |
---|---|
Open | 43.41 |
Bid | 43.60 |
Ask | 43.66 |
Day's Range | 43.14 - 45.60 |
52 Week Range | 30.04 - 63.68 |
Volume | 2,207,237 |
Market Cap | 3.44B |
PE Ratio (TTM) | -9.696 |
EPS (TTM) | -4.5 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 2,186,283 |
Chart
About CRISPR Therapeutics AG - Common Shares (CRSP)
Crispr Therapeutics is a biopharmaceutical company that focuses on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing technology. The company aims to harness the potential of genetic editing to treat various conditions, including genetic disorders, cancer, and autoimmune diseases. Through a combination of innovative research and strategic collaborations, Crispr Therapeutics is dedicated to advancing its pipeline of therapies and ultimately improving patient outcomes and quality of life. Read More
News & Press Releases
Via Benzinga · June 17, 2025
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.
Via Investor's Business Daily · June 17, 2025
Cathie Wood is bullish on biotech companies using gene sequencing, AI, and CRISPR tech to cure previously untreatable diseases.
Via Benzinga · June 9, 2025

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to bear more fruit.
Via The Motley Fool · June 3, 2025

Via The Motley Fool · June 2, 2025
These companies are just starting to realize the potential in up-and-coming fields, like AI and gene editing.
Via The Motley Fool · May 20, 2025
Via The Motley Fool · May 20, 2025
Via The Motley Fool · May 18, 2025
CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders
Via MarketBeat · May 16, 2025

Via The Motley Fool · May 14, 2025
The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline.
Via The Motley Fool · May 12, 2025
The planets are lining up for these three stocks' underlying companies.
Via The Motley Fool · May 10, 2025
In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs.
Via The Motley Fool · May 8, 2025
CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025.
Via Benzinga · May 7, 2025
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.
Via Benzinga · May 7, 2025
Via Benzinga · May 7, 2025
Via Benzinga · May 7, 2025
The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.
Via Investor's Business Daily · May 6, 2025
On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs.
Via Benzinga · April 30, 2025
Via The Motley Fool · April 20, 2025